In commemoration of World Asthma Day 2024, Alkem Laboratories (Alkem) has announced a nationwide initiative titled "Reliever Free India," with plans to conduct 600 to 700 camps across India. Teaming up with nearly 100 hospitals in tier-1 and tier-2 cities, the initiative aims to redefine asthma management by advocating a shift from reliance on reliever medications to prioritizing controller medications. 

Reliever medications provide rapid relief during asthma episodes by opening up airways, while controller medications are taken regularly to prevent symptoms and reduce airway inflammation. Following a successful inaugural year, Alkem is intensifying its efforts in the campaign's second year.

Asthma affects a staggering 262 million individuals globally, manifesting in recurrent wheezing, breathlessness, chest tightness, and coughing episodes. Despite strides in medical advancements, asthma poses a significant challenge for both patients and healthcare providers. Alkem acknowledges the pivotal role of education in empowering individuals to effectively manage their asthma and lead fulfilling lives.

The spokesperson for Alkem Laboratories stated, “Since the inception of our campaign, we've engaged in over 500 camps. This year, we're ramping up our commitment by organizing a minimum of 600 camps and clinics to raise awareness about asthma and its management. Our objective is to equip patients with the knowledge necessary to take charge of their health. Through the 'Reliever Free India' initiative, we're advocating for a proactive approach to asthma management, aiming to enhance outcomes and elevate the quality of life for those living with this condition.”

The "Reliever Free India" campaign underscores the significance of utilizing controller medications for optimal asthma management. While reliever medications offer immediate relief during asthma attacks, they fail to address the underlying inflammation that characterizes the condition's chronic nature. Over-reliance on relievers can lead to subpar long-term outcomes and heightened risk of exacerbations.

Through this campaign, Alkem Laboratories endeavors to educate patients, healthcare professionals, and the public at large about the advantages of controller medications in preventing asthma symptoms and reducing reliance on rescue medication.

On this World Asthma Day, Alkem Laboratories extends an invitation to all to unite in raising awareness, fostering comprehension, and empowering individuals with asthma to lead fulfilling lives. Together, a world can be created where asthma ceases to be a barrier to a healthy and gratifying existence.